Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | UNG | P13051 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590945 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CYP2A6UNGMAOA | |
| SCHEMBL3735918 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CYP2A6UNGMAOA | |
| SCHEMBL20356021 | 0.74 | CYP1A2 (0.42) | ALDH1A1CYP2A6DAODDONFE2L2 | |
| SCHEMBL29952947 | 0.74 | HPRT1 (0.42) | ERN1ALDH1A1SMN1; SMN2CYP2A6KIF11 | |
| SCHEMBL27791456 | 0.73 | ALDH1A1 (0.52) | ALDH1A1CYP2A6 | |
| SCHEMBL29952933 | 0.73 | PTGER4 (0.43) | PTGER4ERN1ALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL4108450 | 0.73 | PTGER4 (0.43) | PTGER4ERN1ALDH1A1SMN1; SMN2CYP2A6 | |
| SCHEMBL9797581 | 0.71 | CYP2A6 (0.41) | ALDH1A1CYP2A6 | |
| SCHEMBL4112541 | 0.71 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL29788341 | 0.71 | ALDH1A1 (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887533-B2 | Fluorinated oxaanthracenes and their use in liquid-crystal mixtures | CLARIANT INTERNATIONAL, LTD. (CH) | 2005-05-03 | — | — | US | disclosed |
| US-20040245498-A1 | Fluorinated oxaanthracenes and their use in liquid-crystal mixtures | AZ ELECTRONIC MATERIALS (GERMANY) GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040245498-A1 | Fluorinated oxaanthracenes and their use in liquid-crystal mixtures | FRG1, CXCR1, CCR1 | PTGER4 805/4885ERN1 2672/4885ALDH1A1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.